UNSPSC 51283216: Triacetyloleandomycin or troleandomycin

This classification denotes a macrolide antibiotic with the molecular formula C41H67NO15, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier C4DZ64560D, chemically known as oleandomycin, triacetyl- but more generally known as triacetyloleandomycin, which bears U.S. National Institutes of Health Compound Identifier 17675. The European Medicines Agency schedules Troleandomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11333MIG.

UNSPSC 51283216 Triacetyloleandomycin or troleandomycin is a Commodity code nominally covering a specific macrolide antibiotic, but recent state and local opportunities tagged under this code show minimal alignment with its narrow pharmaceutical definition. The solicitations reveal a disconnect between the code's nominal scope and actual procurement activity: Seminole County, Florida is bidding naloxone and drug deactivation systems for community health; Tampa is sourcing medical and first aid supplies for fire rescue operations; Texas HHS is gathering vendor information on direct-to-manufacturer prescription programs; and Minnesota MMCAP is establishing multi-state contracts for generic pharmaceuticals and OTC products across government facilities. None of these procurements specifically target triacetyloleandomycin or narrow-spectrum macrolide antibiotics. The code shows little relevant recent activity aligned with its stated pharmaceutical product line.

Issuing bodies include county health departments (Seminole County), city purchasing offices (Tampa), state health agencies (Texas), and cooperative purchasing alliances administered by state procurement offices (Minnesota MMCAP serving multiple states including Oregon). Geographic spread includes Florida, Texas, Minnesota, and Oregon in the visible opportunities, though the cooperative purchasing vehicle extends participation across state lines. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems with a July 26, 2026 response deadline; Tampa's sheltered-market IFB for medical and first aid supplies designated for SLBEs with an estimated contract value of $700,000 and a March 13, 2026 deadline; and Minnesota MMCAP's RFP for generic pharmaceuticals and OTC products with responses due March 26, 2026. The code's nominal focus on a specific antibiotic does not match the health-supply and generic-pharmaceutical procurement activity visible in the recent record.